Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...

Structure Therapeutics (GPCR) announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

Investing.com -- Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock soared 28.8% in premarket trading Monday after the company announced positive topline data from its ACCESS clinical program for ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Shenzhen, Zhenjiang, Xiamen and Nanchang – approached developing low-carbon policies over the course of almost a decade ...

Real-time security clearances are becoming increasingly common in manufacturing of advanced-node semiconductors, where data ...

A Fast Shift Toward Smarter Presales In 2025 Presales move fast this year, and many traders now want early-stage crypto ...

(Dec 10): Coupang CEO Park Dae-jun resigned over his failure to prevent South Korea’s largest-ever data breach, which set off ...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

ECHEMI announced a continued expansion of its global reach as a chemical sourcing platform serving industrial buyers across ...

Industry feedback signals growing pushback against India’s plan to license all “legally accessed” content for AI training.